

## Supplemental Approvals

**Generic Name (Trade Name—Company)**

March 31, 2011

**Uses/Notes**

**Prevention of herpes zoster (shingles) in patients 50 to 59 years of age**

**Varicella zoster vaccine, live, attenuated**

**(Zostavax—Merck)**

**Approved for use in younger patients**

[Zostavax](#) was originally approved for patients 60 years and older. Data from a placebo-controlled, double-blind study involving 22,439 patients who were 50 to 59 years of age showed that administration of the vaccine reduced the risk of developing zoster by 69.8% over a median monitoring period of 1.3 years. Injection-site reactions were the most commonly observed adverse events in this patient population.

**Source URL:**

<http://www.aphanet.org/approved-use-younger-patients>

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.